Back to search

Article

Antisense oligonucleotide therapy for SCN2A gain-of-function epilepsy

2020-09-11

Abstract excerpt

The clinical spectrum associated with SCN2A de novo mutations (DNMs) continues to expand and includes autism spectrum disorder with or without seizures, in addition to early and late seizure onset developmental and epileptic encephalopathies (DEEs). Recent biophysical studies on SCN2A variants suggest that the majority of early seizure onset DEE DNMs cause gain of function. Gain of function in SCN2A, the principa...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
92bf5397-920b-5102-96d2-6c0142e03ced
DOI
10.1101/2020.09.09.289900
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Antisense oligonucleotide therapy for SCN2A gain-of-function epilepsyDOI 10.1101/2020.09.09.289900
Select a neighboring publication to make it the new centre.